Obesity Management

The late-breaking findings at ADA 2022 suggest patients were more often prescribed oral semaglutide by primary care physicians than endocrinologists.

The diabetologist and professor discusses new findings from the ReTUNE trial, which disparage the utility of BMI in defining diabetes risk and remission opportunity.

New post hoc data from the STEP 1 and 4 trials show an approximate 60% risk reduction of type 2 diabetes over 10 years versus placebo.

A month and a half after topline results were announced in April, full data from SURMOUNT-1 was presented at ADA 2022 and demonstrate tirzepatide in 5 mg, 10 mg, or 15 mg doses provides superior weight loss compared to placebo therapy, with this weight loss maintained throughout the duration of the trial.

New data from DDW 2022 show inpatient mortality rates were lower in patients with history of bariatric surgery.

Both the regulation of cues intervention and ROC with behavioral weight loss were found successful in individuals with high levels of food responsiveness.

Adolescents with a GLP-1 RA prescription within year of T2D diagnosis were more probable to be in better glycemic control and less probable to be prescribed insulin.

A continued discussion into misconceptions surrounding obesity treatments and how to better empower patients seeking out treatment.

Dr. Charles Vega suggestion doctors be less prescriptive in suggestion diets to patients.

Drugs like semaglutide are able to treat both diabetes and obesity.

A discussion into available pharmacotherapy for obesity and the uptake in practice of newer agents.

Jennifer Green discussed weight management and obesity during the annual Pri-Med West conference.

Type 2 diabetes can be more aggressive in younger patients.

Participants with obesity or overweight lost up to 22.5% of their body weight with tirzepatide treatment.

Tirzepatide met both coprimary endpoints in SURMOUNT-1, with use contributing to reductions in body weight of up to 22.5% during the 72-week trial and more than 60% of those receiving the 15 mg dose achieving body weight reductions of 20% or more.

Each weight-loss regimen had similar success in obesity management, regardless of patients reducing their calorie consumption through time-restricted eating or through calorie restriction alone.

Patients from the lowest BMI, HbA1c, SBP, and LDL-C population quartile had 3.9, 3.8, 1.9, and 0.9 years of additional life expectancy, respectively.

The conference will take place in-person from from Friday, April 27 - Saturday, May 1 in Atlanta, Georgia and will feature both Proficiency and Masters tracks.

The prevalence of NAFLD in the pediatric population has increased in recent years.

A multi-disciplinary approach could help better manage obesity following bariatric surgery.

A discussion into broadening the findings of the SuperWIN trial and its potential effects on a larger, more at-risk population.

Dylan Steen, MD discusses positive findings from the trial on links between personalized education and DASH diet adherence.

The therapy is indicated for conditions associated with hypogonadism in adult males.

With the newest indication, the GLP-1 agonist is now available in 3 different doses for diabetic adults.

Higher BMI in overweight category at midlife was associated with a greater burden of overall and CVD morbidity, as well as higher health care costs in older adulthood.